Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in Aktien #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aktienkurs
$0.00244926
Marktkapitalisierung
$51.67K
Veränderung (1 Tag)
5.88%
Veränderung (1 Jahr)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategorie

P/B-Verhältnis für Nuformix plc (NFX)
P/B-Verhältnis zum March 2026 TTM: 5.52
Laut den neuesten Finanzberichten und dem Aktienkurs von Nuformix plc beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 5.52. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 0.64.
P/B-Verlauf für Nuformix plc von 2014 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 5.52 6.74%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
5.6573 2.51%
DK
6.3842 15.68%
US
2.4551 -55.51%
US
4.364 -20.92%
BE
2.5504 -53.79%
AU